Pseudomyxoma peritonei surgery: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (11 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Pseudomyxoma peritonei}} | {{Pseudomyxoma peritonei}} | ||
{{CMG}}{{AE}}{{PSD}} | {{CMG}}{{AE}}{{Nnasiri}}{{PSD}} | ||
==Overview== | ==Overview== | ||
Pseudomyxoma peritonei is a rare clinical syndrome characterized by the accumulation of [[ascites]] and [[Mucin|mucins]] in the [[peritoneum]], mainly arising from the [[appendix]]. The mainstay of therapy in patients with pseudomyxoma peritonei is cytoreductive surgery combined with [[intraperitoneal]] [[Chemotherapy|chemotherapeutic infusion]]. | |||
==Surgery== | ==Surgery== | ||
*Surgery is the mainstay of treatment for pseudomyxoma peritonei. The feasibility of surgery depends on the stage of pseudomyxoma peritonei at diagnosis. | *[[Surgery]] is the mainstay of treatment for pseudomyxoma peritonei. The traditional approach was repeated surgical [[debulking]], feasibility of [[surgery]] depends on the stage of pseudomyxoma peritonei at [[diagnosis]].<ref name="pmid17036382">{{cite journal |vauthors=Qu ZB, Liu LX |title=Management of pseudomyxoma peritonei |journal=World J. Gastroenterol. |volume=12 |issue=38 |pages=6124–7 |date=October 2006 |pmid=17036382 |pmc=4088104 |doi= |url=}}</ref> | ||
*A more aggressive approach | *A more aggressive approach is called cytoreductive surgery (CRS), in combination with [[Hyperthermic intraperitoneal chemoperfusion|hyperthermic intraperitoneal chemotherapy]] (HIPEC) which has following advantage: | ||
**Targeting of the microscopic disease | |||
**Minimal systemic exposure and less toxicity | |||
**Improved [[Chemotherapy|chemotherapeutic drug]] penetration by warming to 42 degree centigerade and direct [[Peritoneum|peritoneal]] infusion.<ref name="pmid19567401">{{cite journal |vauthors=Vaira M, Cioppa T, DE Marco G, Bing C, D'Amico S, D'Alessandro M, Fiorentini G, DE Simone M |title=Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience |journal=In Vivo |volume=23 |issue=4 |pages=639–44 |date=2009 |pmid=19567401 |doi= |url=}}</ref><ref name="pmid21874418">{{cite journal |vauthors=Kitai T, Kawashima M, Yamanaka K, Ichijima K, Fujii H, Mashima S, Shimahara Y |title=Cytoreductive surgery with intraperitoneal chemotherapy to treat pseudomyxoma peritonei at nonspecialized hospitals |journal=Surg. Today |volume=41 |issue=9 |pages=1219–23 |date=September 2011 |pmid=21874418 |doi=10.1007/s00595-010-4495-6 |url=}}</ref> | |||
== References == | == References == | ||
| Line 24: | Line 21: | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Gastroenterology]] | |||
[[Category:Surgery]] | |||
Latest revision as of 13:34, 3 April 2019
|
Pseudomyxoma peritonei Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pseudomyxoma peritonei surgery On the Web |
|
American Roentgen Ray Society Images of Pseudomyxoma peritonei surgery |
|
Risk calculators and risk factors for Pseudomyxoma peritonei surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Nima Nasiri, M.D.[2]Parminder Dhingra, M.D. [3]
Overview
Pseudomyxoma peritonei is a rare clinical syndrome characterized by the accumulation of ascites and mucins in the peritoneum, mainly arising from the appendix. The mainstay of therapy in patients with pseudomyxoma peritonei is cytoreductive surgery combined with intraperitoneal chemotherapeutic infusion.
Surgery
- Surgery is the mainstay of treatment for pseudomyxoma peritonei. The traditional approach was repeated surgical debulking, feasibility of surgery depends on the stage of pseudomyxoma peritonei at diagnosis.[1]
- A more aggressive approach is called cytoreductive surgery (CRS), in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) which has following advantage:
- Targeting of the microscopic disease
- Minimal systemic exposure and less toxicity
- Improved chemotherapeutic drug penetration by warming to 42 degree centigerade and direct peritoneal infusion.[2][3]
References
- ↑ Qu ZB, Liu LX (October 2006). "Management of pseudomyxoma peritonei". World J. Gastroenterol. 12 (38): 6124–7. PMC 4088104. PMID 17036382.
- ↑ Vaira M, Cioppa T, DE Marco G, Bing C, D'Amico S, D'Alessandro M, Fiorentini G, DE Simone M (2009). "Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience". In Vivo. 23 (4): 639–44. PMID 19567401.
- ↑ Kitai T, Kawashima M, Yamanaka K, Ichijima K, Fujii H, Mashima S, Shimahara Y (September 2011). "Cytoreductive surgery with intraperitoneal chemotherapy to treat pseudomyxoma peritonei at nonspecialized hospitals". Surg. Today. 41 (9): 1219–23. doi:10.1007/s00595-010-4495-6. PMID 21874418.